Approval · Notice of Compliance 26705 · 2021
ESOMEPRAZOLE: Notice of Compliance 26705
Issued September 23, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26705
- Date
- September 23, 2021
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- Licensing Agreement Between Two Companies
- Canadian reference product
- NEXIUM (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESOMEPRAZOLE | 02520699 | Marketed |
| ESOMEPRAZOLE | 02520702 | Marketed |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM 20 MG per TAB
- ESOMEPRAZOLE MAGNESIUM 40 MG per TAB